AQST Investors Have Opportunity to Lead Aquestive Therapeutics, Inc. Securities Fraud Lawsuit
There is a quiet, rhythmic hum from the office radiator—or maybe it’s just the old pipes—that makes the mid-afternoon news cycle feel even more clinical than usual. Rosen Law Firm is out today with a reminder for investors who held Aquestive Therapeutics, Inc. (NASDAQ: AQST) stock between June 16, 2025, and January 8, 2026. If that window hits home for your portfolio, you have until May 4, 2026, to step up as a lead plaintiff.
It’s the standard legal machinery. A lawsuit is already moving through the court system, and the claim alleges that Aquestive didn’t quite play fair with the details regarding their New Drug Application for Anaphylm. Specifically, the complaint points to those tricky human factor issues—the packaging, the way you actually use the sublingual film, the labeling, that sort of thing—which supposedly weren’t disclosed clearly enough.
Investors are being told they might be owed compensation. The firm is pushing the contingency fee angle, meaning no out-of-pocket costs, but you really have to pick your representation carefully. There’s a lot of noise in this space—some firms are just middlemen, frankly—so doing a bit of homework on who is actually running the litigation is probably a smart move. Or at least, it’s a move.
Rosen Law says they have the track record to back it up, citing their history with large settlements and rankings from 2013 onward. Laurence Rosen, a partner there, even got a ‘Titan of Plaintiffs’ Bar’ nod back in 2020. They are clearly positioning themselves as the go-to team for this specific fight, even though, technically, no class has been certified yet.
What happens next is up to the individual investors. You can sit tight and remain an absent class member, or you can try to take the wheel by filing to be a lead plaintiff. Just don’t wait past that May deadline. You don’t have to hire them, obviously—people can choose their own counsel—but the clock is definitely ticking.
It’s a lot to process, especially when the market is acting the way it has been lately. Sometimes it feels like these filings just pile up on the desk, one after another.